Week 96 SOLSTICE trial results advance Vir Biotechnology pursuit of chronic hepatitis D treatment

Week 96 SOLSTICE trial results advance Vir Biotechnology pursuit of chronic hepatitis D treatment
Vir Biotechnology SOLSTICE trial reports

Vir Biotechnology has announced new data from its Phase 2 SOLSTICE trial demonstrating sustained suppression of hepatitis D virus (HDV) at Week 96.

The results, shared during the final day of EASL2026, underscore the potential progress in therapies for chronic hepatitis D (CHD), a field with significant unmet medical need. The company highlighted coverage of its findings in the American Journal of Managed Care. Vir Biotechnology expressed appreciation for ongoing engagement within the hepatology community as the SOLSTICE study progresses.

Vir Biotechnology recently presented data on the effects of body mass index in chronic hepatitis delta patients from its Phase 2 SOLSTICE study at EASL2026 here. Earlier this year, CEO Marianne De Backer participated in a live fireside chat at the Bank of America Securities 2026 Healthcare Conference here. The company continues to update stakeholders on its clinical progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.